Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study.

Young ChangSang Gyune KimSoung-Won JeongJae-Young JangJeong-Ju YooSae-Hwan LeeYoung-Seok KimHong-Soo KimHyun Woong Lee Su-Yeon Park

Published in: Journal of clinical medicine (2021)

In patients with chronic hepatitis B, the efficacy of TDO was noninferior to that of TDF, with a significant decrease in the HBcrAg titer and improved renal function.

Keyphrases

hepatitis b virus
open label
newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
clinical trial
prognostic factors
antiretroviral therapy
squamous cell carcinoma
study protocol
patient reported outcomes
liver fibrosis
cross sectional
phase ii study
phase iii
phase ii